## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.9% below STRENGTH zone (4.0-10.0%); PEG 1.94 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($247.04)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Is the Options Market Predicting a Spike in Labcorp Holdings Stock?**
- Source: TradingView — Track All Markets | 20251215T140849 | Somewhat-Bearish | Relevance: 100%
- The options market is showing a high implied volatility for Labcorp Holdings (LH) stock, particularly with the Feb 20, 2026 $135 Call. This suggests investors anticipate a significant price movement, possibly due to an upcoming event. Despite this, analysts currently rate Labcorp Holdings as a Zacks Rank #3 (Hold), with recent downward revisions to earnings estimates.

**2. LabCorp Holdings Inc. (LH) Files Form 8-K with SEC**
- Source: GuruFocus | 20251216T012500 | Neutral | Relevance: 100%
- LabCorp Holdings Inc. (LH) has filed a Form 8-K with the SEC on December 9, 2025, to disclose significant company developments. Although specific details of the filing were not provided in this release, such reports typically announce material events like mergers, leadership changes, or other financial or operational impacts. Investors are encouraged to review the full document on the SEC's website for complete information.

**3. Cofactor Genomics, Inc. announced that it has received funding from Labcorp Holdings Inc., Ascension Ventures, LLC**
- Source: marketscreener.com | 20251215T190838 | Somewhat-Bullish | Relevance: 100%
- Cofactor Genomics, Inc. has secured a new round of funding on December 15, 2025. The investment saw participation from new investor Labcorp Holdings Inc. and existing investor Ascension Ventures, LLC. As part of the transaction, Cofactor Genomics issued convertible preferred shares.

**4. How is Labcorp Holdings' stock performance compared to other healthcare stocks?**
- Source: MSN | 20251215T010808 | Neutral | Relevance: 100%
- The article discusses the stock performance of Labcorp Holdings (LH) relative to other healthcare stocks. It provides an overview of how Labcorp is faring within its sector, offering a comparative analysis.

**5. Is There Now An Opportunity In Labcorp Holdings Inc. (NYSE:LH)?**
- Source: 富途牛牛 | 20251216T000807 | Somewhat-Bullish | Relevance: 96%
- Labcorp Holdings Inc. (NYSE:LH) has experienced significant price movements, rising to US$291 before dropping to US$247, and is currently trading at US$264. The company's share price appears reasonably valued compared to industry peers, with a P/E ratio slightly above the industry average. Future earnings are expected to increase by 58%, suggesting a highly optimistic outlook.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.94 elevated, pricing in significant growth expectations. Forward P/E 14.7x stretched relative to 7% growth. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.4B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.94 |
| Forward P/E | 14.7 |
| Current P/E | 15.8 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.1% to -1.9% (+1.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.9pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.00x) but short-term weakness (below SMA20). RSI neutral at 42. OFD pattern: -FTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.89% (CS: 26) | Neutral |
| RSI_14 | 41.9 | Neutral |
| MACD Histogram | -0.10 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.966x | Below |
| vs SMA200 | 1.002x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $258.06
- **Stop Loss:** $247.04 (4.3% risk)
- **Target:** $269.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $23,225.40
- **Portfolio %:** 23.23%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*